Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial

NCT07746388 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Nsclc
NSCLC Stage II
NSCLC, Stage III
NSCLC Stage IIIB
Resectable Lung Non-Small Cell Carcinoma

Interventions

DRUG: Cemiplimab

Sponsor

University of Maryland, Baltimore

Collaborators

[object Object]